Manfred Rüdiger

Company: Ariceum Therapeutics

Job title: Chief Executive Officer

Seminars:

Outlining a Best-in-class SST2 Antagonist in SCLC & a Cancer Cell DNA Targeted- Auger-Electron Approach in Solid Tumors 12:45 pm

Using Satoreotide, aka JR11, labelled with Lu, Ac or Tb in SCLC Understanding the impact of changing tracer versus changing isotope Introducing a radioactively labelled small molecule to target tumor cell DNA using Auger emittersRead more

day: Day One ESC AM